Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
The US government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under ...
The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.
We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...
The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...
The FDA on Tuesday approves Ozempic, the weight loss drug made by Novo Nordisk, for the treatment of chronic kidney disease ...
Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...
1d
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback